Who is sponsoring NCT02823847?

NCT02823847 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02823847?

Interventions in NCT02823847: Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy.

What condition does NCT02823847 study?

NCT02823847 studies Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus.

Is NCT02823847 still recruiting?

NCT02823847 is currently completed. Last updated 14 February 2022.

Last reviewed 2022-02-14 · How we verify

NCT02823847

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

Completed EARLY_PHASE1 Last updated 14 February 2022

What this trial tests

EARLY_PHASE1 trial testing Screening Interview in Malignant Neoplasms of Mesothelial and Soft Tissue in 44 participants. Completed in 26 July 2021.

Timeline

30 June 2016

Primary endpoint
26 July 2021

26 July 2021

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	44
Start date	30 June 2016
Primary completion	26 July 2021
Estimated completion	26 July 2021
Sites	1 location across United States

Drugs / interventions tested

Screening Interview
Carbon Monoxide Test
Self-Help Materials
Visual Oral Screening Examination
Direct Fluorescent Oral Visualization Examination
Oral Biopsy

Conditions studied

Malignant Neoplasms of Mesothelial and Soft Tissue — all drugs for Malignant Neoplasms of Mesothelial and Soft Tissue →
Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Malignant Neoplasms of Mesothelial and Soft Tissue or Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn how a new method for performing oral (mouth) exams can help doctors check for suspicious lesions (called premalignant and malignant oral lesions \[PMOL\]) in the mouth of HIV-infected smokers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The effect of non-AIDS-defining cancers on people living with HIV.
Chiao EY, Coghill A, Kizub D, Fink V, et al · · 2021 · cited 60× · PMID 34087151 · DOI 10.1016/s1470-2045(21)00137-6
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
Bender Ignacio RA, Lin LL, Rajdev L, Chiao E. · · 2018 · cited 9× · PMID 30099376 · DOI 10.6004/jnccn.2018.7064

Verify or expand the search:

Other recruiting trials for Malignant Neoplasms of Mesothelial and Soft Tissue

Currently open trials in the same condition.

NCT03435952 — Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT · Phase 1 · active not recruiting
NCT03093909 — Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases · Phase 1 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02823847 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 14 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02823847.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing